从靶向单药治疗到BRAF-MEK联合抑制剂以及用于黑色素瘤治疗的综合基因组分析。 - Suppr

Suppr

超能文献

From targeted monotherapy to combined BRAF-MEK inhibitors and integrated genome analysis for melanoma treatment.

作者信息

Roukos Dimitrios H, Papaloukas Costas, Tzaphlidou Margaret

出版信息

Future Oncol. 2013 Jan;9(1):5-8. doi: 10.2217/fon.12.169.

DOI:10.2217/fon.12.169

PMID:23252557

Abstract

摘要

相似文献

From targeted monotherapy to combined BRAF-MEK inhibitors and integrated genome analysis for melanoma treatment.

Future Oncol. 2013 Jan;9(1):5-8. doi: 10.2217/fon.12.169.

Targeted Therapy for Melanoma.

Cancer Treat Res. 2016;167:251-62. doi: 10.1007/978-3-319-22539-5_10.

[BRAF inhibitor and MEK inhibitor].

Gan To Kagaku Ryoho. 2015 Apr;42(4):428-33.

Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.

Cancer Treat Rev. 2015 Jun;41(6):519-26. doi: 10.1016/j.ctrv.2015.04.010. Epub 2015 Apr 29.

MEK and RAF inhibitors for BRAF-mutated cancers.

Expert Rev Mol Med. 2012 Oct 12;14:e17. doi: 10.1017/erm.2012.11.

Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged.

Cancer Cell. 2014 Nov 10;26(5):603-4. doi: 10.1016/j.ccell.2014.10.017.

[Update on BRAF and MEK inhibitors in the treatment of malignant melanoma].

J Dtsch Dermatol Ges. 2015 May;13(5):485-7. doi: 10.1111/ddg.12692.

Protein kinase inhibitors in melanoma.

Expert Opin Pharmacother. 2013 Nov;14(16):2195-201. doi: 10.1517/14656566.2013.827172. Epub 2013 Aug 31.

Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1638-1640. doi: 10.1111/jdv.14268. Epub 2017 May 8.

A new standard of care for metastatic melanoma?

Lancet Oncol. 2015 Jan;16(1):e8. doi: 10.1016/S1470-2045(14)71138-6. Epub 2014 Nov 21.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

From targeted monotherapy to combined BRAF-MEK inhibitors and integrated genome analysis for melanoma treatment.

Future Oncol. 2013 Jan;9(1):5-8. doi: 10.2217/fon.12.169.

Targeted Therapy for Melanoma.

Cancer Treat Res. 2016;167:251-62. doi: 10.1007/978-3-319-22539-5_10.

[BRAF inhibitor and MEK inhibitor].

Gan To Kagaku Ryoho. 2015 Apr;42(4):428-33.

Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.

Cancer Treat Rev. 2015 Jun;41(6):519-26. doi: 10.1016/j.ctrv.2015.04.010. Epub 2015 Apr 29.

MEK and RAF inhibitors for BRAF-mutated cancers.

Expert Rev Mol Med. 2012 Oct 12;14:e17. doi: 10.1017/erm.2012.11.

Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged.

Cancer Cell. 2014 Nov 10;26(5):603-4. doi: 10.1016/j.ccell.2014.10.017.

[Update on BRAF and MEK inhibitors in the treatment of malignant melanoma].

J Dtsch Dermatol Ges. 2015 May;13(5):485-7. doi: 10.1111/ddg.12692.

Protein kinase inhibitors in melanoma.

Expert Opin Pharmacother. 2013 Nov;14(16):2195-201. doi: 10.1517/14656566.2013.827172. Epub 2013 Aug 31.

Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1638-1640. doi: 10.1111/jdv.14268. Epub 2017 May 8.

A new standard of care for metastatic melanoma?

Lancet Oncol. 2015 Jan;16(1):e8. doi: 10.1016/S1470-2045(14)71138-6. Epub 2014 Nov 21.